SCHEMBL3247318

SCHEMBL3247318

N=C(CCc1ccccc1)C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 6/20 0.49
FAAH O00519 3/20 0.49
KEAP1 Q14145 1/20 0.48
ALDH1A1 P00352 1/20 0.45
FFAR1 O14842 1/20 0.45
TDP1 Q9NUW8 2/20 0.43
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
NOS1 P29475 1/20 0.42
KMT2A Q03164 1/20 0.42
KCNJ11 Q14654 1/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC3 O15379 1/20 0.41
MAPK1 P28482 1/20 0.41
ADRA1A P35348 1/20 0.41
HDAC4 P56524 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27957621 0.80 FFAR1 (0.42) FAAHALDH1A1FFAR1TDP1KMT2A
SCHEMBL27957660 0.76 F2RL1 (0.53) ALDH1A1FFAR1POLBGAA
SCHEMBL1274684 0.75 CES1 (0.73) CES1FAAHKEAP1ALDH1A1FFAR1
SCHEMBL20973256 0.75 CES1 (0.49) CES1FAAHKEAP1ALDH1A1FFAR1
Phenyl Propionic Acid SCHEMBL27428011 0.75 KEAP1 (0.79) CES1FAAHKEAP1ALDH1A1FFAR1
Phenyl Propionic Acid SCHEMBL27403516 0.73 KEAP1 (0.76) CES1FAAHKEAP1ALDH1A1FFAR1
SCHEMBL27604433 0.73 CES1 (0.47) CES1FAAHKEAP1ALDH1A1FFAR1
SCHEMBL28285164 0.72 KEAP1 (0.50) KEAP1ALDH1A1FFAR1TDP1HDAC2
SCHEMBL6191952 0.71 KEAP1 (0.54) KEAP1ALDH1A1FFAR1TDP1HDAC2
SCHEMBL1891210 0.71 NOS1 (0.57) KEAP1ALDH1A1FFAR1TDP1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021254493-A1 CYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF 上海翊石医药科技有限公司 2021-12-23 WO disclosed
EP-2181996-A1 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2010-05-05 EP disclosed
US-7312212-B2 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2007-12-25 US disclosed
US-20050159411-A1 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2005-07-21 US disclosed
EP-1470125-A1 AMINOPIPERIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2004-10-27 EP disclosed
WO-2003064421-A1 AMINOPIPERIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159411-A1 Aminopiperidine derivatives AMPD2, AMPD3, NPEPPS CES1 4220/4885FAAH 1624/4885KEAP1 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.